Chenyang is biostatistics grad student at @emoryrollins.bsky.social -- mcDETECT works with datasets generated with #genomics platforms such as Xenium 5K, MERSCOPE and CosMx. In AD mouse model, can reveal alterations in RNA patterns and neuronal states before observable neuronal loss. 2/2

We also noticed that Green is appearing at a STAT Summit session on "Inside the Upheaval at NIH" with @jeremymberg.bsky.social (how convenient for #ASHG25 folks)

Hu’s lab integrates single-cell and spatial data with clinical and histological information to uncover disease mechanisms and accelerate precision medicine. 4/4 jianhu-lab.org/people/jian-...

McEachin’s multiomic approach reveals disease-specific molecular changes, facilitating biomarker and targeted therapy development. An example of his work was published in Cell this month. 3/4 news.emory.edu/stories/2025...

Andersen is a global leader in the use of assembloids - mini-organ systems that model brain-spinal cord interactions - to study ALS (amyotrophic lateral sclerosis). 2/4

That is changing all the time, it seems

This wouldn’t have been possible without our amazing collaborators and support (Emory HERCULES, @emorygenetics.bsky.social) and the bold and fearless ambition of @maureenbiologies.bsky.social

Could we then observe Pb being actively taken up by human neural cells? Yes! A human Pb sensor (leadmium) let us literally watch Pb uptake over the course of several hours into human neurons and astrocytes.

One of the first challenges we had was figuring out how much Pb to give to human cells to reflect true exposure levels. We dug through the literature for relevant Pb levels in brain and then empirically correlated this with exposure paradigms that resulted in similar tissue levels in human organoids

We decided to investigate one of the most infamous and widely prevalent neurotoxicants—Lead (Pb). In the US, approximately 2.5% of pregnant women exhibit high blood Pb levels (!!!) What is the consequence of this on the developing human brain?

Why does one #ALS patient respond more than others to ASOs? This phenomenon has appeared again recently with another ASO therapy ulefnersen/jacifusen - with a couple patients showing "unprecedented" response! Important for the field to find out. 4/x www.als.org/blog/two-tri...

In particular, case #6 displayed a "robust" decrease in polyGP, protein produced from toxic C9orf72 gene expansion, and increase in neurofilament, an ALS treatment response biomarker. 3/x

While the parent #ALS clinical trial was disappointing (see link), a few patients responded more than others on the molecular level -- without clinical improvement. 2/x eprints.whiterose.ac.uk/id/eprint/22...